BPCIA At Fed. Cir.: Awaiting Guidance On Patent Dance

Fish attorney Jenny Shmuel provided expert analysis to Law360 about the BPCIA and the Federal Circuit. The Federal Circuit panel heard arguments in Amgen v. Apotex (17-1010) on October 2 and theirarticle delves into how the upcoming ruling has the potential to shape BPCIA litigation going forward.

To read the full article, visit Law360.

Authors: Jenny Shmuel, Tasha Francis

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.

Law360: BPCIA At Fed. Circ.: Awaiting Guidance On Patent Dance

Biosimilars 2021 Year in Review

Fish Attorneys Author Biosimilar Development Article, "Regulatory And Legislative Actions Set The Tone For Biosimilars In 2021"

Biosimilars 2020 Year in Review

Fish Attorneys Author Biosimilar Development Article, "An Update On 2020 U.S. Biosimilars Regulation & Litigation"

A Biosimilar's Guide to the BPCIA Patent Dance: Five Key Questions for Every Biosimilar Applicant to Consider

Insulin and Other Biological Products Previously Regulated as "Drugs" Transition to Biologics Regulation on March 23, 2020

Increasing Competition in the Biologic Market Through Truthful Advertising

White Paper | Biosimilars - 2019 Year in Review

Fish Attorneys Author Fourth Article of a Four-Part Series in Biosimilar Development, "Biosimilar Litigation Review: Anticompetitive Conduct Cases &...

Fish Attorneys Author Part Three of a Four-Part Series in Biosimilar Development, "Biosimilar Litigation Review: BPCIA Federal Circuit Appeals Pending &...

How a Second Trump Presidency Could Shape IP

Texas Patent Litigation Monthly Wrap-Up: October 2024

Trade Secrets: A Powerful Alternative to Noncompete Agreements

Should the Experimental Use Exception Be Broadened?

Duty of Disclosure and Consistency Requirements for Statements to PTO and Other Government Agencies

Taking a Good Deposition, Part II: Asking the Right Kind of Questions and Asking Them in the Right Way

The Final Word on an Alleged Infringer’s Intent in a Hatch-Waxman Safe Harbor Analysis

Preparing Your Company for Hatch-Waxman

Texas Patent Litigation Monthly Wrap-Up: July 2024

Texas Patent Litigation Monthly Wrap-Up: June 2024